JNJ - Johnson & Johnson

NYSE - NYSE Delayed Price. Currency in USD
126.66
-0.89 (-0.70%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close127.55
Open128.00
Bid0.00 x 0
Ask0.00 x 0
Day's Range126.17 - 128.30
52 Week Range122.15 - 148.32
Volume7,743,916
Avg. Volume8,176,917
Market Cap339.783B
Beta0.59
PE Ratio (TTM)267.22
EPS (TTM)0.47
Earnings DateJul 17, 2018
Forward Dividend & Yield3.36 (2.57%)
Ex-Dividend Date2018-02-26
1y Target Est149.05
Trade prices are not sourced from all markets
  • Kentucky Governor Bevin: I'm not on board with JNJ opioid...
    CNBC Videos4 days ago

    Kentucky Governor Bevin: I'm not on board with JNJ opioid...

    Kentucky Governor Matt Bevin discusses his state District Attorney suing Johnson & Johnson for contributing to the opioid epidemic through deceptive marketing.

  • MARKETS: The real test for stocks is coming from the bond market
    Yahoo Finance Video4 days ago

    MARKETS: The real test for stocks is coming from the bond market

    Yahoo Finance's Jared Blikre and Alexis Christoforous break down the latest market action.

  • Trump touts economy as stocks rally
    Fox Business Videos5 days ago

    Trump touts economy as stocks rally

    Wall Street Journal columnist Veronica Dagher, Fox News political contributor Tammy Bruce and Fox News contributor Robert Wolf on the strength of the U.S. economy and how President Trump’s tax cuts have impacted consumers.

  • Motley Fool45 minutes ago

    Johnson & Johnson's First-Quarter 2018 Earnings Review

    We discuss the pros and cons for J&J’s latest quarterly results, plus Alkermes gets a do-over and Celldex flops.

  • Barrons.comyesterday

    [$$] Square, eBay, and the Future of Money

    Earnings per share were higher despite a higher tax rate and a lower contribution from other income. What we didn’t like about the first quarter: 1) the pharma mix was not optimal, as key drugs Actelion, Darzalex, and Xarelto all missed our estimate. U.S. Remicade was down 16% Y/Y, in line with our estimate, but we were hoping for better.

  • 4 Blue-Chip Stocks to Buy Ahead of Eye-Popping Earnings
    InvestorPlace2 days ago

    4 Blue-Chip Stocks to Buy Ahead of Eye-Popping Earnings

    After a spell of high volatility driven by uncertainty over global trade policy and the threat of rise in prices of essential commodities, Wall Street is looking for some respite in the upcoming earnings season. Given the positive trend, investing in blue-chip stocks that are likely to make the most of the earnings season seems judicious. This is because such stocks are positioned to report impressive earnings results as they mostly have a strong balance sheet and solid cash flow.

  • Pharma Stock Roundup: NVS, JNJ Q1 Sales & Earnings Top, MRK & BMY Active at AACR
    Zacks2 days ago

    Pharma Stock Roundup: NVS, JNJ Q1 Sales & Earnings Top, MRK & BMY Active at AACR

    Novartis (NVS) and J&J (JNJ) deliver strong Q1 results. Merck (MRK) and Bristol Myers (BMY) present lung cancer data at AACR.

  • J&J, Novartis' Q1 Earnings Impress: Will Others Follow Suit?
    Zacks2 days ago

    J&J, Novartis' Q1 Earnings Impress: Will Others Follow Suit?

    Johnson & Johnson (JNJ) and Novartis reported strong first-quarter 2018 earnings results earlier this week.

  • AbbVie And Other Great Pharma And Biotech Income Stocks
    Simply Wall St.2 days ago

    AbbVie And Other Great Pharma And Biotech Income Stocks

    Pharmaceutical and biotech stocks are rarely seen as effective dividend stocks. Although drugs are also relatively non-cyclical these stocks are often impacted by ever-changing regulatory environment and the strength ofRead More...

  • Dow 30 Stock Roundup: AmEx, Goldman, IBM, JNJ, P&G, UNH Earnings Impress
    Zacks2 days ago

    Dow 30 Stock Roundup: AmEx, Goldman, IBM, JNJ, P&G, UNH Earnings Impress

    The Dow experienced a particularly volatile week as earnings results took center stage.

  • CNBC2 days ago

    Johnson & Johnson is betting on vision care and expanding beyond contacts

    J&J has added surgical products and a contact subscription service to its lineup of Acuvue contact lenses.

  • CNBC2 days ago

    Johnson & Johnson is betting on vision care and expanding beyond contacts

    J&J has added surgical products and a contact subscription service to its lineup of Acuvue contact lenses.

  • TheStreet.com3 days ago

    P&G, GE and IBM Need to Innovate; Has Starbucks' Stock Grown Ice Cold?--ICYMI

    issues were still top of mind to just about everyone as investors continued to drive the stock down as well. It's tough for some investors to find a positive view of the Seattle-based coffee house company. It's been trading sideways for close to three years, producing a 2% return over the last 12 months compared with 15% for the S&P and a somewhat pricey 21 times P/E multiple for a food and beverage company, all of which make an unappetizing menu choice for investors, never mind the company's moral and ethical dilemmas, says Stephen Guilfoyle.

  • Healthcare ETFs in Focus After Johnson & Johnson Q1 Earnings
    Zacks3 days ago

    Healthcare ETFs in Focus After Johnson & Johnson Q1 Earnings

    Johnson & Johnson reports Q1 results with both revenues and EPS beating estimates.

  • 3 Drugs That Are Moving the Needle at Johnson & Johnson
    Motley Fool4 days ago

    3 Drugs That Are Moving the Needle at Johnson & Johnson

    Johnson & Johnson owes a lot of its early success this year to rapidly growing sales of three key products.

  • Barrons.com4 days ago

    After the Bell: Dow Drops 38 Points Because…IBM

    The major equity indexes barely moved today, as a postearnings drop from International Business Machines (IBM) was canceled out by gains from Textron (TXT), Intuitive Surgical (ISRG), and others. Ultimately, it shows once again that it's as much a market of stocks as it is a stock market. The Dow Jones Industrial Average dropped 38.56 points, or 0.2%, to 24,748.07, while the S&P 500 ticked up 0.1% to 2708.64, and the Nasdaq Composite advanced 0.2% to 7295.24.

  • Kentucky Gov. Matt Bevin slams state AG's lawsuit against J&J: 'These are political moves'
    CNBC4 days ago

    Kentucky Gov. Matt Bevin slams state AG's lawsuit against J&J: 'These are political moves'

    "I'm not on board with just about anything that he does," Gov. Matt Bevin said of Kentucky Attorney General Andy Beshear.

  • Reuters4 days ago

    Kentucky accuses J&J of contributing to opioid epidemic

    Kentucky's attorney general on Wednesday sued Johnson & Johnson, accusing the pharmaceutical manufacturer of devising a deceptive marketing scheme that mischaracterized the risk of opioid abuse and addiction. The lawsuit by Kentucky Attorney General Andy Beshear was his fifth to date seeking to hold a drug manufacturer or distributor responsible for its role in the national opioid epidemic.

  • MarketWatch4 days ago

    IBM and J&J stocks cut 100 points from Dow industrials in early trading

    The Dow Jones Industrial Average on Wednesday morning was wrestling with sharp declines in IBM and Johnson & Johnson. Shares of International Business Machines Corp. were off 7.2%, or about $11.50, which equates to a drop of about 80 points, while J&J's stock was contributing a further 24-point retreat in the benchmark, down 2.7%, or about $3.50, in recent action. Overall, the Dow was still managing to rise by about 24 points, or less than 0.1%, at 24,802, with J&J and IBM's tumble slightly offset by gains in Home Depot Inc. Caterpillar Inc. and Boeing Co. 's stocks.

  • Location revealed: Johnson & Johnson institute's new HQ to go in Lake Nona's Medical City
    American City Business Journals4 days ago

    Location revealed: Johnson & Johnson institute's new HQ to go in Lake Nona's Medical City

    This $18 million building will be next to the Sanford Burnham Prebys Medical Discovery Institute in southeast Orlando.

  • The resume of the future will tell employers who you are, and not just what you’ve done
    Quartz4 days ago

    The resume of the future will tell employers who you are, and not just what you’ve done

    Resumes are a poor proxy for a human being. Whether on paper or LinkedIn, they may tell an employer about a job seeker’s experience and credentials, but they’re frustratingly silent about almost everything else. They have virtually nothing to say about a candidate’s personality, or their character, or their ability to persuade and communicate—all soft…

  • The Wall Street Journal4 days ago

    [$$] Johnson & Johnson Raises Sales Outlook

    Johnson & Johnson reported higher-than-expected sales in its latest quarter and boosted its sales outlook for the year despite ongoing pricing pressures for its prescription drugs and medical devices. J&J said it planned to cut costs in its supply chain by $600 million to $800 million a year by 2022. To carry out the changes, J&J expects it will take $1.9 billion to $2.3 billion in charges over the next several years.

  • Reuters5 days ago

    U.S. drug agency proposes rules to rein in opioid manufacturing

    The U.S. government on Tuesday proposed tightening rules governing the amount of prescription opioid painkillers that drugmakers can manufacture in a given year, in hopes of reining in the deadly opioid epidemic. The Drug Enforcement Administration's proposed changes to its regulations over addictive drug manufacturing quotas were announced by Attorney General Jeff Sessions. The plan could sharply reduce the annual production of painkillers.

  • What to Look for as First-Quarter Earnings Hit Around the Globe
    Bloomberg5 days ago

    What to Look for as First-Quarter Earnings Hit Around the Globe

    Trade, taxes and China are the main themes to watch for heading into first-quarter earnings, along with a spate of potential deals.

  • Associated Press5 days ago

    UnitedHealth and Alphabet climb; Tesla and Comerica skid

    Stocks that moved substantially or traded heavily Tuesday: UnitedHealth Group Inc., up $8.23 to $238.55 The health insurer raised its annual profit forecast after a strong first quarter. Tesla Inc., down ...